• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dabigatran etexilate and treatment of acute venous thromboembolism in children.

作者信息

Kenet Gili

机构信息

National Hemophilia Center, Coagulation Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel.

出版信息

Lancet Haematol. 2021 Jan;8(1):e2-e3. doi: 10.1016/S2352-3026(20)30397-5. Epub 2020 Dec 5.

DOI:10.1016/S2352-3026(20)30397-5
PMID:33290736
Abstract
摘要

相似文献

1
Dabigatran etexilate and treatment of acute venous thromboembolism in children.
Lancet Haematol. 2021 Jan;8(1):e2-e3. doi: 10.1016/S2352-3026(20)30397-5. Epub 2020 Dec 5.
2
The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.在英国，达比加群酯与华法林相比用于急性静脉血栓栓塞症治疗及延长抗凝治疗的成本效益分析
Thromb Haemost. 2015 Oct;114(4):778-92. doi: 10.1160/TH14-12-1027. Epub 2015 Aug 13.
3
Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.在英国背景下，达比加群酯与利伐沙班在静脉血栓栓塞治疗及延长抗凝治疗中的间接比较和成本效益分析
J Med Econ. 2016;19(1):1-10. doi: 10.3111/13696998.2015.1078340. Epub 2015 Sep 21.
4
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.RE-COVERY DVT/PE：一项关于急性静脉血栓栓塞症的前瞻性观察性研究的原理与设计，重点关注达比加群酯。
Thromb Haemost. 2017 Jan 26;117(2):415-421. doi: 10.1160/TH16-07-0566. Epub 2016 Nov 17.
5
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.达比加群与华法林在存在血栓形成倾向的急性静脉血栓栓塞症患者中的疗效：来自RE-COVER®、RE-COVER™ II和RE-MEDY™的研究结果
Vasc Med. 2016 Dec;21(6):506-514. doi: 10.1177/1358863X16668588. Epub 2016 Nov 1.
6
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.达比加群酯与依诺肝素预防全髋关节置换术后静脉血栓栓塞的随机、双盲、非劣效性试验
Lancet. 2007 Sep 15;370(9591):949-56. doi: 10.1016/S0140-6736(07)61445-7.
7
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.直接口服抗凝剂（DOACs）治疗静脉血栓栓塞症的获益风险差异评估：聚焦达比加群
Drug Des Devel Ther. 2015 Jul 9;9:3557-69. doi: 10.2147/DDDT.S70299. eCollection 2015.
8
New anticoagulants for treatment of venous thromboembolism.新型抗凝药物治疗静脉血栓栓塞症。
Eur J Intern Med. 2012 Dec;23(8):692-5. doi: 10.1016/j.ejim.2012.10.001. Epub 2012 Oct 23.
9
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.静脉血栓栓塞症管理中的当前及新出现策略：达比加群的获益-风险评估
Vasc Health Risk Manag. 2015 May 27;11:271-82. doi: 10.2147/VHRM.S62595. eCollection 2015.
10
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.达比加群酯治疗儿童急性静脉血栓栓塞症（DIVERSITY）：一项随机、对照、开放标签、2b/3 期、非劣效性试验。
Lancet Haematol. 2021 Jan;8(1):e22-e33. doi: 10.1016/S2352-3026(20)30368-9. Epub 2020 Dec 5.

引用本文的文献

1
Direct oral anticoagulant safety during breastfeeding: a narrative review.母乳喂养期间直接口服抗凝剂的安全性：叙述性综述。
Eur J Clin Pharmacol. 2021 Oct;77(10):1465-1471. doi: 10.1007/s00228-021-03154-5. Epub 2021 May 8.